# A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

> **NCT03101280** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 29 (actual)

## Conditions studied

- Gynecologic Neoplasms

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT03101280
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-27
- **Primary completion:** 2020-08-11
- **Final completion:** 2020-08-11
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03101280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03101280, "A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03101280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*